|STUDY 1: Cadavid et al. (2009)1
Randomized clinical trial
|Patients||Treatment arms/study duration|
(Treatment-naive patients with relapsing
Primary endpoint: Number of combined active lesions (CAL) per scan in the first year, with the patient as the unit of analysis.
Figure: MRI activity in patients with multiple sclerosis randomised to treatment with Glatirmer Acetate or interferon beta-1b (IFNβ-1b)
- Similar median (75th percentile) CAL per patient per scan for months 1–12, 0.63 (2.76) for IFNβ-1b, and 0.58 (2.45) for GA (p=0.58).
- There were no differences in new lesion or clinical relapses for 2 years.
Patients with relapsing multiple sclerosis randomized to interferon beta 1b or Glatiramer Acetate showed similar MRI and clinical activity.1